Royalty Report: Drugs, Central Nervous System, Disease – Collection: 303746

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Central Nervous System
  • Disease
  • Therapeutic
  • Pain
  • Biotechnology
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 303746

License Grant
The parties entered into an exclusive worldwide license agreement to develop and commercialize V158866, a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.
License Property
V158866 is for post-traumatic stress disorder and other central nervous system diseases.  V158866 is a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.

Field of Use
Licensee will utilize the inhibitor, V158866, for post-traumatic stress disorder and other central nervous system diseases.

Licensee is a biopharmaceutical company committed to developing treatments for psychiatric disorders.

IPSCIO Record ID: 369272

License Grant
University hereby grants to Licensee the world-wide right and license to the Patent Rights set forth to the full end of the term of each patent included therein unless sooner terminated as hereinafter provided. This grant is expressly subject to the rights of the U.S. Government, if any.

In order to establish a period of exclusivity for Licensee, University hereby agrees that it shall not grant any other license to make, have made, use, lease and sell the Patent Rights during the period of time commencing with the Effective Date of this Agreement and terminating with the full end of the term of this Agreement, unless sooner terminated as hereinafter provided.

Licensee shall have the right to sublicense worldwide any of the rights, privileges and license granted hereunder.

License Property
Patent Rights' shall mean

5,616,707 – Compounds which are useful for prevention and treatment of central nervous system disorders

5,726,316 – Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Field of Use
Ispronicline (TC-1734). Ispronicline is a novel small molecule that we are developing as an oral treatment for conditions marked by cognitive impairment that afflict elderly persons, including Alzheimer’s disease and age associated memory impairment, commonly referred to as AAMI

Field of use is for nicotinic compounds for use in therapeutic applications, including for prevention and treatment of central nervous system disorders.

IPSCIO Record ID: 6588

License Grant
Licensor hereby grants to Licensee an exclusive, with right to sublicense, license or sublicense, as applicable, under the Infinity Know-How and Infinity Patent Rights to Commercialize FAAH Products in the Territory.
License Property
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.

The Parties are interested in forming an alliance whose goal is to develop and commercialize FAAH Products in the United States.

The Company has commenced clinical development of its internally discovered drug candidate, IPI-940, a novel inhibitor of the enzyme fatty acid amide hydrolase, or FAAH. After Phase 1 investigation, select Licensees will have the right to assume worldwide development and commercialization activities under the Licensor's FAAH program.

IPI-940, a potential treatment for a broad range of neuropathic and inflammatory pain conditions, is a selective, orally available inhibitor of FAAH. Inhibitors of FAAH have the ability to potentiate the magnitude and duration of the body’s endogenous analgesic agents through their effects on the endocannabinoid system. After Phase 1 investigation, the Licensees will have the right to assume worldwide development and commercialization activities under the FAAH program.

IPSCIO Record ID: 4255

License Grant
Licensor hereby grants to Licensee during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How and Infinity Patent Rights to Commercialize FAAH Products in the Territory.
License Property
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.

An innovative drug discovery and development company, today announced that it has commenced clinical development of its fourth internally discovered drug candidate, IPI-940, a novel inhibitor of the enzyme fatty acid amide hydrolase, or FAAH. After Phase 1 investigation, two Licensees will have the right to assume worldwide development and commercialization activities under the Licensor's FAAH program.

Field of Use
IPI-940, a potential treatment for a broad range of neuropathic and inflammatory pain conditions, is a selective, orally available inhibitor of FAAH. Inhibitors of FAAH have the ability to potentiate the magnitude and duration of the body’s endogenous analgesic agents through their effects on the endocannabinoid system. After Phase 1 investigation, the Licensees will have the right to assume worldwide development and commercialization activities under the FAAH program.

IPSCIO Record ID: 182113

License Grant
The Company entered into a MLA to license the rights to Licensor programs.
License Property
This program is for a Oral EPO.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.

Field of Use
This agreement is for the drug industry.

IPSCIO Record ID: 367292

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license, with the right to grant sub-licenses solely pursuant to Agreement, in the Licensor Intellectual Property Rights and the Licensor Licensed Product identified in the Notice Letter dated March 14, 2007 to develop, have developed, make, have made, use, have used, sell, have sold and offer for sale the Licensor Licensed Product in the Field anywhere in the Territory.
License Property
Licensed Product as used herein shall mean molindone and it salts, racemic mixtures, isomers, derivatives, and analogues thereof as licensed to Licensee in accordance with the terms and conditions of this Agreement.

Patent Rights
6,897,212 – Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones
6,613,763 – Use of molindone to treat oppositional defiant disorder and conduct disorder

Field of Use
Field shall mean for the treatment, diagnosis or prevention of central nervous system related diseases and indications in humans and animals.

IPSCIO Record ID: 273531

License Grant
The Licensor granted an exclusive license to patent rights.
License Property
The patent rights relating to combinations of a muscarinic activator with a muscarinic inhibitor.z
Field of Use
The field of use is for the treatment of central nervous system disorders.  Licensee is a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions.

IPSCIO Record ID: 182114

License Grant
The Company entered into an agreement to license the rights to Licensor DGAT-1 programs.
License Property
“DGAT-1 Compounds” means Metabasis’ MB11210 compound, and any other compounds comprised by the DGAT-1 Patents, and any salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers, polymorphs, and derivatives of such compounds.

Diacylglycerol O-acyltransferase 1 is an enzyme that in humans is encoded by the DGAT1 gene.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.

Field of Use
The portfolio of orally available small molecule inhibitors of the enzyme DGAT-1 for the potential treatment of lipid disorders such as obesity and dyslipidemia.

IPSCIO Record ID: 183242

License Grant
The parties entered an agreement for MM-151 program covering methods of treating colorectal cancer.
License Property
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
Field of Use
This agreement is for the drug industry.

IPSCIO Record ID: 183243

License Grant
The parties entered an agreement for MM-141 program covering methods of treating pancreatic cancer.
License Property
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
Field of Use
This agreement is for the drug industry.

IPSCIO Record ID: 245927

License Grant
Licensor, a University, hereby grants to Company and its affiliates for the term (a) a royalty-bearing license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the field in the territory and to develop and perform Licensed Processes in the field in the territory;  (b) a royalty-bearing license to use the tangible property to develop, make, have made, use, sell, offer to sell, lease and import Licensed Products in the field in the territory and to develop and perform Licensed Processes in the field in the territory.
License Property
Patent Rights shall mean (a) the United States and international patents listed.
US Patent Application #10/108,195 titled Methods and Products related to FGF Dimerization.

Licensed Process shall mean any process that, absent the license granted hereunder, would infringe one or more valid claims of the Patent Rights or which uses a Licensed Product.

United States Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'

International (non-U.S.) Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'

WO Patent Application Serial No US02/09517, Filed on March 27, 2002
Entitled METHODS AND PRODUCTS RELATED TO FGF DIMERIZATION

Field of Use
Field shall mean human therapeutics for the treatment of neurological disorders and conditions, which shall include disorders and conditions pertaining to the central nervous, peripheral nervous, autonomic nervous, and neuromuscular systems.

patents pertain to a novel molecule for treatment of neurological disorders, including stroke.

IPSCIO Record ID: 182115

License Grant
This agreement is for one of licensors programs.
License Property
This is for the KLM465. Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
Field of Use
This agreement is for the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.